Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine

Many argue that phase I cancer trials are a therapeutic option for eligible patients. I question this position and offer a more nuanced view that differentiates between types of trials. Patients seeking treatment might legitimately pursue phase I trials, although labelling all phase I trials as therapeutic contradicts the spirit of evidence-based medicine.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Fukuda, Y. K. et al. Risks and benefits of phase 1 oncology trials, 2001 through 2012. J. Clin. Oncol. 32, 2552–2552 (2014).

    Article  Google Scholar 

  2. 2.

    Roberts, T. G. et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292, 2130–2140 (2004).

    CAS  Article  Google Scholar 

  3. 3.

    Enzinger, A. C. et al. Clinical trial participation as part of end-of-life cancer care: associations with medical care and quality of life near death. J. Pain Symptom Manage. 47, 1078–1090 (2014).

    Article  Google Scholar 

  4. 4.

    Wright, A. A. et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 300, 1665–1673 (2008).

    CAS  Article  Google Scholar 

  5. 5.

    Hay, M. et al. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40–51 (2014).

    CAS  Article  Google Scholar 

  6. 6.

    American Society of Clinical Oncology. Insurance Coverage of Clinical Trials. ASCO.org https://www.asco.org/research-progress/clinical-trials/insurance-coverage-clinical-trials (2016).

  7. 7.

    Marquart, J., Chen, E. Y. & Prasad, V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 4, 1093–1098 (2018).

    Article  Google Scholar 

  8. 8.

    Temel, J. S. et al. Keeping expectations in check with immune checkpoint inhibitors. J. Clin. Oncol. 36, 1654–1657 (2018).

    Article  Google Scholar 

  9. 9.

    American Society of Clinical Oncology. Critical role of phase I clinical trials in cancer treatment. J. Clin. Oncol. 15, 853–859 (1997).

    Article  Google Scholar 

  10. 10.

    Miller, M. Phase I cancer trials: a collusion of misunderstanding. Hastings Cent. Rep. 30, 34–43 (2000).

    CAS  Article  Google Scholar 

  11. 11.

    Anderson, J. A. & Kimmelman, J. Are phase 1 trials therapeutic? risk, ethics, and division of labor. Bioethics 28, 138–146 (2014).

    Article  Google Scholar 

  12. 12.

    Kimmelman, J. Is participation in cancer phase i trials really therapeutic? J. Clin. Oncol. 35, 135–138 (2016).

    Article  Google Scholar 

  13. 13.

    Anderson, J. A. & Kimmelman, J. Extending clinical equipoise to phase 1 trials involving patients: unresolved problems. Kennedy Inst. Eth. J. 20, 75–98 (2010).

    Article  Google Scholar 

  14. 14.

    Pentz, R. D. et al. Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer 118, 4571–4578 (2012).

    Article  Google Scholar 

  15. 15.

    Truog, R. D. The United Kingdom sets limits on experimental treatments: the case of Charlie Gard. JAMA 318, 1001–1002 (2017).

    Article  Google Scholar 

Download references

Acknowledgements

The work of the author is funded by CIHR (PJT-148726).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jonathan Kimmelman.

Ethics declarations

Competing interests

The author serves in a remunerative capacity on a DSMB for a (non-cancer) phase I trial of Ultragenyx.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kimmelman, J. Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine. Nat Rev Clin Oncol 16, 719–720 (2019). https://doi.org/10.1038/s41571-019-0264-7

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing